1
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
------------------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934
------------------------
Date of Report (Date of earliest event reported): March 21, 1996
--------------
IMMUNOGEN, INC.
---------------
(Exact name of registrant as specified in its charter)
Massachusetts 0-17999 04-2726691
- ------------- ------- ----------
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
128 Sidney Street, Cambridge, Massachusetts 02139
-------------------------------------------------
Registrant's telephone number, including area code: (617) 661-9312
--------------
2
ITEM 5. OTHER EVENTS.
- ------- -------------
On March 21, 1996, the Registrant publicly disseminated a press release
announcing that the Registrant plans to issue $5 million of convertible
debentures pursuant to Regulation D of the Securities Act of 1933 in two
installments: $2.5 million of debentures on or about March 25, 1996 and, as
part of the same transaction, the remaining $2.5 million immediately upon
approval by the Company's Shareholders of an increase in the Company's
authorized common stock. The information contained in the press release is
incorporated herein by reference and filed as Exhibit 99.1 hereto.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.
- ------- ----------------------------------
(c) Exhibits.
99.1 The Registrant's Press Release dated March 21, 1996.
99.2 Securities Purchase Agreement dated as of March 15, 1996 by
and among the Registrant and Capital Ventures International.
99.3 Registration Rights Agreement dated as of March 15, 1996 by
and among the Registrant and Capital Ventures International.
99.4 Letter Agreement dated as of March 21, 1996 by and among the
Registrant and Capital Ventures International regarding the
Securities Purchase Agreement dated as of March 15, 1996
(Exhibit 99.2 hereto)
2
3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
ImmunoGen, Inc.
---------------
(Registrant)
Date: March 29, 1996 /s/ Frank J. Pocher
-------------- -------------------
Frank J. Pocher
Vice President and
principal financial officer
3
4
EXHIBIT INDEX
-------------
Exhibit Sequential
Number Description Page Number
- ------ ----------- -----------
99.1 The Registrant's Press Release 5
dated March 21, 1996.
99.2 Securities Purchase Agreement 7
dated as of March 15, 1996 by
and among the Registrant and
Capital Ventures International
99.3 Registration Rights Agreement 46
dated as of March 15, 1996 by
and among the Registrant and
Capital Ventures International
99.4 Letter Agreement dated as of 63
March 21, 1996 by and among the
Registrant and Capital Ventures
International regarding the
Securities Purchase Agreement
dated as of March 15, 1996
(Exhibit 99.2 hereto)
4